Anifrolumab (Saphnelo) listed in MB

March 10, 2024 – Lupus Canada is pleased to share that Saphnelo has been listed in Manitoba effective April 1, 2024.

For more information, please visit https://www.gov.mb.ca/health/mdbif/docs/bulletins/bulletin131.pdf

Lupus Blog Articles:

Lupus and Heart Health: Understanding Cardiovascular Risk in SLE

Read

OCT Screening Hydroxychloroquine Coverage | Lupus Canada Advocacy

Read

The Lupus Canada Annual General Meeting 2026

Read